author-photo

Anna Marina Liberati

University of Perugia

414

Papers

9039

Citations

Citation Trend

Filter By

Papers (414) Sort By

Journal Conference Others

P-224: Pomalidomide, bortezomib, and dexamethasone after 1 prior line of therapy in relapsed or refractory multiple myeloma (RRMM): A safety subanalysis of the phase 3 OPTIMISMM trial

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
Brentuximab-vedotin and bendamustine produce long-term clinical benefit in patients with refractory or relapsed classical Hodgkin lymphoma: a multicenter real-life experience

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
Long-term analyses from L-MIND, a phase II study of tafasitamab (MOR208) combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL).

2021 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (2)
Updated results of the fil “miro” study, a multicenter phase II trial combining local radiotherapy and MRD-driven immunotherapy in early-stage follicular lymphoma

2021 Hematological Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics.

2021 European Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (1)
Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma (S-ERMM) in a Pooled Dataset of 2190 Patients.

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE.

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (1)
SAFETY AND EFFICACY OF ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MAGNOLIA PHASE 2 STUDY)

2021 Hematological Oncology
Show All
- Source
- Cite
- Save
Citations (0)